High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas

Cancer Investigation

Volumn 14, Issue 3, 1996, Pages 239-242

  Güllü, Ibrahim ^a,b   Yalçin, Şuayib ^a   Tekuzman, Gülten ^a   Barişta, Ibrahim ^a   Alkiş, Necati ^a   Çelik, Ismail ^a   Zengin, Nurullah ^a   Güler, Nilüfer ^a   Kars, Ayşe ^a   Baltali, Eşmen ^a   Kansu, Emin ^a   Firat, Dinçer ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Turan Gunes Bulvari   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IFOSFAMIDE; MESNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SARCOMA;

EID: 9444298411     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609012146     Document Type: Article

References (16)

1. Cancer statistics. CA Cancer J Clin 38:5-22, 1988.
2. Schoenfeld C, Rosenbaum C, Horton J, et al: A comparison of adriamycin versus vincristine and adriamycin and cyclophosphamide for advanced sarcoma. Cancer 50:2757-2762, 1982.
3. Pinedo HM, Bramwell VHC, Mouridson MD, et al: High dose ifosfamide by infusion with mesna in advanced soft tissue sarcomas. Cancer Treatment Rev 10(Suppl A):163-164, 1983.
4. Antman K, Elias A: Chemotherapy of advanced soft tissue sarcomas. Semin Surg Oncol 4:53-58, 1988.
5. Stuart-Harris R: Harper PG, Kaye SB, et al: High dose ifosfamide by infusion with mesna in advanced soft tissue sarcomas. Cancer Treat Rev 10(Suppl A):163-164; 1983.
6. Weiss RB: Ifosfamide vs cyclophosphamide in cancer therapy. Oncology 5:67-76, 1991.
7. Dirix LY, Van Oosterom AT: The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing sarcoma and osteosarcoma: A review. Semin Oncol 17(Suppl 4):50-57, 1990.
8. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207-214, 1981.
9. Benjamin RS, Wiemik PH, Bachur NT: Adriamycin chemotherapy: Efficacy, safety, and pharmacological basis of intermittent single high dose schedule. Cancer 33:19-27, 1974.
10. Creagan ET, Hahn RG, Ahmann DL, et al: A clinical trial with adriamycin in advanced sarcomas. Oncology 34:90-91, 1978.
11. Gottlieb JA, Benjamine RS, Baker LH, et al: Role of DTIC in the chemotherapy of sarcomas. Cancer Treat Rep 60:199-203, 1976.
12. Hoefer-Janker H, Scheef U, Gunther U, et al: Ergahrungen mit der fractionierten ifosfamide-strosstherapie bei generalisierten malignant tumoren. Med Welt 26:972-979, 1975.
13. Bruhl P, Gunther U, Hoefer-Janker H, et al: Results obtained with fractionated ifosfamide massive dose treatment in generalized massive tumors. Int J Clin Pharmacol 14:29-37, 1976.
14. Wiltshow E, Westbury G, Harme C, et al: Ifosfamide and Mesna with and without adriamycin in soft tissue sarcoma. Cancer Chemother Pharmacol 11:69-72, 1983.
15. Antman KH, Ryan L, Elias A, et al: Response to ifosfamide and Mesna: 124 previously treated patients with metastatic or unresectable carcinoma. J Clin Oncol 1:126-131, 1989.
16. Chevallier B, Leyvraz S, Oliver JP, et al. Epirubicine and ifosfamide in advanced soft tissue sarcoma: A phase II study. Cancer Invest 11:135-139, 1993.